The June 2019 article indicated 8 patients entered the trial with no measurable disease and 5 of these ended with no measurable disease from this group while 3 progressed. Also 1 patient out of 30 that actually had at least one vaccine given had a complete response with just over two year data available. Bottom line is there is a long way to go with this tech and way behind L Phase 3 and their Poly ICLC adjuvant trials. Best wishes.
News 
Market Data 
Discover 
